Wedbush Reaffirms Outperform Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued on Tuesday, RTT News reports. They currently have a $33.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 101.10% from the company’s current price.

Several other analysts have also recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday, April 22nd. HC Wainwright dropped their price target on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $16.41 on Tuesday. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $18.07. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -6.89 and a beta of -1.44. The firm has a 50 day simple moving average of $15.46 and a 200 day simple moving average of $14.17.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, analysts expect that Day One Biopharmaceuticals will post -2.67 EPS for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares of the company’s stock, valued at $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Charles N. York II sold 2,666 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The disclosure for this sale can be found here. Insiders sold 195,247 shares of company stock valued at $3,376,817 over the last quarter. Insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. Vanguard Group Inc. raised its holdings in shares of Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares during the period. Franklin Resources Inc. raised its stake in Day One Biopharmaceuticals by 4.2% during the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after buying an additional 169,463 shares during the period. Braidwell LP boosted its holdings in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. Finally, Polar Capital Holdings Plc grew its stake in Day One Biopharmaceuticals by 9.0% in the third quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company’s stock valued at $23,742,000 after acquiring an additional 160,385 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.